Humira

(Adalimumab)

ApprovedMonoclonal antibody

Adalimumab is used to treat inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease by reducing the immune system's inflammatory response. It helps relieve pain, swelling, and other symptoms caused by these autoimmune diseases.[2] Humira is currently approved and in use across 33 indications[4].[1]

Humira is one of 581 monoclonal antibody programs targeting Psoriasis Vulgaris. It is currently in Approved.

Indications

413

Total Trials

Active Trials

580

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Psoriasis VulgarisUnknown

PanuveitisUnknown

Juvenile Idiopathic ArthritisNot yet recruiting

Ankylosing SpondylitisNot yet recruiting

OsteomyelitisActive, not recruiting

Vogt-Koyanagi-Harada DiseaseActive, not recruiting

Pustular PsoriasisUnknown

Immune System DiseaseUnknown

Juvenile Psoriatic ArthritisRecruiting

Rheumatic DiseaseRecruiting

Psoriasis VulgarisPreclinical

Unknown

PanuveitisPreclinical

Unknown

Juvenile Idiopathic ArthritisApproved

Not yet recruiting

Ankylosing SpondylitisApproved

Not yet recruiting

OsteomyelitisPreclinical

Active, not recruiting

Vogt-Koyanagi-Harada DiseasePreclinical

Active, not recruiting

Pustular PsoriasisPreclinical

Unknown

Immune System DiseasePreclinical

Unknown

Juvenile Psoriatic ArthritisPhase 3

Recruiting

Rheumatic DiseasePhase 2

Recruiting

Showing 10 of 33 indications

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Humira

Novartis

Approved

7 2

Rinvoq

AbbVie

Phase 3

4 3

Imfinzi

AstraZeneca

Phase 3

1 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

7 5

Rapamune

PPrism Pharmaceuticals

Phase 3

5 6

Taxotere

AAvyxa

Phase 3

4 7

Romiplostim N01

Qilu Pharmaceutical Co., Ltd.

Phase 3

1 8

HSK39297

Haisco Pharmaceutical Group Co., Ltd.

Phase 3

3 9

INZ-701

IInozyme Pharma

Phase 3

1 10

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Uveitis

NCT05105347

Q1 2027

Post-ApprovalRecruiting

Crohn's Disease

NCT06180382

Q3 2027

Phase 2Not yet recruiting

Uveitis

NCT05874505

Phase 3Active, not recruiting

Rheumatoid Arthritis

NCT04909801

Q4 2027

Phase 3Not yet recruiting

Uveitis

NCT06258915

N/ARecruiting

Takayasu Arteritis

NCT07491913

Clinical

Trials by Indication[1]

Rheumatoid Arthritis41 trials

RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis

Terminated·TTcLand Expression S.A.··NCT03016260·250 enrolled

A Study in Moderate to Severe Rheumatoid Arthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01710358·1,307 enrolled

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

Completed· EMD Serono logo

EMD Serono·Phase 2·NCT00595413·311 enrolled

Show 38 more trials

Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis

Completed· AbbVie logo

AbbVie·Phase 3·NCT00195663·799 enrolled

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 2/3·NCT00647491·352 enrolled

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting·UUniversity of Nebraska·Phase 3·NCT03414502·400 enrolled

Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis

Completed·AAbbott·Phase 4·NCT00420927·1,032 enrolled

An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy

Completed· Roche logo

Roche··NCT01592292·90 enrolled

Effects of Abatacept on Myocarditis in Rheumatoid Arthritis

Terminated·—·Phase 4·NCT03619876·11 enrolled

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

Completed· AbbVie logo

AbbVie·Phase 4·NCT00808509·33 enrolled

Adalimumab in Rheumatoid Arthritis. An Investigation of Wholebody MRI, Conventional MRI, CT and Circulating Biomarkers

Completed·GGlostrup University Hospital, Copenhagen··NCT01029613·40 enrolled

A Canadian Study to Evaluate Early Use of Adalimumab After Methotrexate Failure in Early Rheumatoid Arthritis

Completed· AbbVie logo

AbbVie·Phase 4·NCT01162421·77 enrolled

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04909801·338 enrolled

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

Completed· Astellas logo

Astellas·Phase 4·NCT03737708·21 enrolled

Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)

Completed·UUniversity Hospital, Tours·Phase 4·NCT01382160·69 enrolled

Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00690573·25 enrolled

Anti-TNF Agents for the Treatment of Rheumatoid Arthritis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00837434·63 enrolled

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

Completed·AAbbott·Phase 3·NCT00195702·619 enrolled

Prospective Study on Intensive Early Rheumatoid Arthritis Treatment

Completed·FFondazione IRCCS Policlinico San Matteo di Pavia·Phase 4·NCT00480272·251 enrolled

Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease

Completed·UUnknown Sponsor·Phase 3·NCT02760407·1,648 enrolled

An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis

Completed·SSamsung Bioepis Co., Ltd.·Phase 2·NCT02565810·49 enrolled

A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00233571·796 enrolled

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

Completed· Novartis logo

Novartis·Phase 3·NCT02744755·353 enrolled

A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety

Completed· AbbVie logo

AbbVie·Phase 2·NCT01712178·100 enrolled

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Completed· Gilead logo

Gilead·Phase 3·NCT02889796·1,759 enrolled

Self-injection of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00603993·88 enrolled

Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 4·NCT03100253·208 enrolled

Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid Arthritis

Unknown status·LLeiden University Medical Center·Phase 4·NCT05502731·40 enrolled

Safety and Effectiveness of Adalimumab in Patients Diagnosed With Rheumatoid Arthritis

Completed·AAbbott··NCT01078571·705 enrolled

Targeted Ultrasound in Rheumatoid Arthritis

Completed·UUniversity of Leeds·Phase 4·NCT02056184·183 enrolled

SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.

Completed·JJulia Brown·Phase 4·NCT01295151·122 enrolled

Pharmacokinetic and Safety Study With Adalimumab in Chinese Subjects With Mild Rheumatoid Arthritis

Completed· AbbVie logo

AbbVie·Phase 1·NCT00650156·24 enrolled

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

Approved for marketing·AAbbott··NCT00650026

REstore Working Ability in RheumatoiD Arthritis

Unknown status·TThe Rheumatological Center of Helsinki·Phase 4·NCT01405326·160 enrolled

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis

Approved for marketing·AAbbott··NCT00649545

Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

Completed·AAbbott·Phase 3·NCT00647920·47 enrolled

Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate

Terminated· Takeda logo

Takeda·Phase 2·NCT02393378·7 enrolled

Predictors of the Response to Adalimumab in Rheumatoid Arthritis

Completed·UUniversity Hospital, Rouen·Phase 4·NCT00234234·200 enrolled

Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

Completed·AAbbott·Phase 3·NCT00235872·309 enrolled

Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)

Completed·UUniversity Hospital, Tours·N/A·NCT00497614·8 enrolled

Post-marketing Observational Study in Subjects With Rheumatoid Arthritis

Completed·AAbbott··NCT00234884·3,435 enrolled

Psoriasis24 trials

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Completed·IInnovaderm Research Inc.·Phase 4·NCT00940862·30 enrolled

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02694523·684 enrolled

Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT01970488·350 enrolled

Show 21 more trials

A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate

Completed· AbbVie logo

AbbVie·Phase 3·NCT01251614·114 enrolled

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 3·NCT00237887·1,212 enrolled

The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis

Unknown status·SSinocelltech Ltd.·Phase 3·NCT03927352·330 enrolled

Adalimumab-psoriasis and Small Bowel Lesions

Completed·IInnovaderm Research Inc.·Phase 4·NCT01556672·100 enrolled

Adalimumab in Adult Japanese Subjects With Psoriasis

Completed·AAbbott·Phase 2/3·NCT00647400·147 enrolled

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAbbott·Phase 3·NCT00195676·1,469 enrolled

Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

Completed·JJochen Schmitt.··NCT01812954·1 enrolled

Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Completed·IInnovaderm Research Inc.·Phase 4·NCT01722214·107 enrolled

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Completed·AAlvotech Swiss AG·Phase 3·NCT03849404·413 enrolled

Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis

Completed·AAlvotech Swiss AG·Phase 3·NCT04453137·567 enrolled

Effect of Adalimumab Therapy on Psoriasis Patient

Unknown status·SSohag University·N/A·NCT05889338·140 enrolled

The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis

Unknown status·MMedical University of Vienna·Phase 4·NCT01088165·66 enrolled

Immunoclassification of Psoriasis: a Strategy for Precision Medicine

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT05503875·100 enrolled

A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT01483599·293 enrolled

A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02016482·217 enrolled

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02207231·837 enrolled

Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

Completed· Shanghai Henlius Biotech logo

Shanghai Henlius Biotech·Phase 3·NCT03316781·262 enrolled

Vascular Inflammation in Psoriasis Trial (The VIP Trial)

Completed·UUniversity of Pennsylvania·Phase 4·NCT01553058·97 enrolled

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

Completed· Amgen logo

Amgen·Phase 3·NCT05073315·425 enrolled

An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation

Completed· AbbVie logo

AbbVie·Phase 4·NCT01644396·50 enrolled

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

Completed· AbbVie logo

AbbVie·Phase 4·NCT01265823·150 enrolled

Adalimumab18 trials

A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects

Completed·MMeiji Seika Pharma Co., Ltd.·Phase 1·NCT02927353·180 enrolled

A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab

Completed· AbbVie logo

AbbVie·Phase 2·NCT01502423·61 enrolled

Yuflyma® (Adalimumab), Patient Experience After Switching

Unknown status·CCelltrion HealthCare France··NCT05427942·300 enrolled

Show 15 more trials

Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants

Completed· Amgen logo

Amgen·Phase 1·NCT05995691·179 enrolled

Abatacept Versus Adalimumab Head-to-Head

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00929864·869 enrolled

Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan

Completed·KKeio University·Phase 4·NCT03505008·300 enrolled

Doppler Evaluation in RA Patients After Adalimumab.

Completed·HHamed Rezaei·Phase 4·NCT01609205·60 enrolled

Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806

Completed· AbbVie logo

AbbVie·Phase 3·NCT00686374·100 enrolled

Pharmacokinetics, Safety and Tolerability Study of AVT02 to EU-approved and US-licensed Humira (Adalimumab)

Completed·AAlvotech Swiss AG·Phase 1·NCT03849313·390 enrolled

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

Completed· Pfizer logo

Pfizer·Phase 1·NCT02237729·362 enrolled

Switching From Adalimumab to Infliximab

Completed·UUniversity Hospital, Ghent··NCT01338740·21 enrolled

A Clinical Study With Adalimumab Biosimilar

Completed·LLaboratorios Richmond S.A.C.I.F.·Phase 1·NCT06291948·150 enrolled

ADALISKIAS: Adalimumab for Acute Disc Prolapse

Unknown status·KKuopio University Hospital·Phase 3·NCT01510548·90 enrolled

Adalimumab Microneedles in Healthy Volunteers

Completed·CCentre for Human Drug Research, Netherlands·Phase 1/2·NCT03607903·24 enrolled

Correlation of Serum Adalimumab Levels at an Administration of 40 mg Weekly vs 80 mg Every Two Weeks

Unknown status·HHospital Universitario La Paz·Phase 3·NCT04404517·20 enrolled

Adalimumab Biosimilar in Clinical Practice

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT04808739·604 enrolled

Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.

Completed· AbbVie logo

AbbVie·Phase 2·NCT01561313·64 enrolled

Therapeutic Monitoring of Infliximab and Adalimumab

Unknown status·IIRCCS Burlo Garofolo··NCT06033469·100 enrolled

Uveitis11 trials

A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT04088409·30 enrolled

Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

Recruiting·—·Phase 2·NCT02706704·32 enrolled

Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02929251·112 enrolled

Show 8 more trials

"Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT05874505·60 enrolled

Efficacy and Safety of Adalimumab in Patients With Active Uveitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01138657·239 enrolled

Efficacy and Safety of Adalimumab Plus Medium Dose Oral Glucocorticosteroid for Refractory Behçet's Uveitis

Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT05105347·130 enrolled

Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis

Unknown status·SSun Yat-sen University·Phase 2·NCT04588818·30 enrolled

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01148225·424 enrolled

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

Completed·OOregon Health and Science University·Phase 2·NCT00525902·31 enrolled

The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT05015335·50 enrolled

Treatment FOr Corticosteroid Dependent UveitiS

Not yet recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT06258915·120 enrolled

Ankylosing Spondylitis10 trials

Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study

Unknown status·—·Phase 4·NCT02489760·30 enrolled

Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients

Completed·UUniversidade Nova de Lisboa·Phase 4·NCT02492217·69 enrolled

Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Unknown status·JJagiellonian University·Phase 4·NCT02132234·100 enrolled

Show 7 more trials

REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)

Unknown status·HHanyang University Seoul Hospital·Phase 4·NCT05164198·448 enrolled

The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients

Unknown status·QQilu Hospital of Shandong University·Phase 4·NCT05527444·100 enrolled

Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity

Completed·UUniversity Hospital, Montpellier·N/A·NCT01610947·398 enrolled

Safety and Efficacy of Adalimumab in Patients With Active Ankylosing Spondylitis

Completed·AAbbott·Phase 3·NCT00195819·82 enrolled

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Not yet recruiting·TThe Affiliated Hospital Of Guizhou Medical University·Phase 4·NCT06833112·10 enrolled

Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis

Completed·AAbbott·Phase 3·NCT01114880·344 enrolled

Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)

Completed·UUniversity Hospital, Tours·Phase 4·NCT01895764·110 enrolled

42 more indications

Psoriatic Arthritis10 trials

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Completed· AbbVie logo

AbbVie·Phase 3·NCT03104400·1,705 enrolled

Ultrasound Enthesitis Response in Psoriatic Arthritis

Completed·BBelfast Health and Social Care Trust··NCT03955861·80 enrolled

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 4·NCT03151551·566 enrolled

Show 7 more trials

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Completed·AAbbott·Phase 3·NCT00646178·102 enrolled

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

Completed·AAbbott·Phase 3·NCT00235885·445 enrolled

Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Unknown status·UUniversity of Erlangen-Nürnberg Medical School·Phase 3·NCT04610476·270 enrolled

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study

Completed· Pfizer logo

Pfizer·Phase 3·NCT01877668·422 enrolled

A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)

Completed·AAbbott·Phase 3·NCT00427362·127 enrolled

A Study of Ixekizumab in Participants With Active Psoriatic Arthritis

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01695239·417 enrolled

Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis

Completed· Novartis logo

Novartis·Phase 3·NCT02745080·853 enrolled

Crohn's Disease10 trials

A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's Disease

Withdrawn· UCB logo

UCB·Phase 3·NCT04643483

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

Completed·AAbbott·Phase 3·NCT00195715·777 enrolled

Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION)

Completed·—··NCT04131504·239 enrolled

Show 7 more trials

Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

Completed·AAbbott·Phase 3·NCT00105300·300 enrolled

Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss of Response or Biomarker Activity to Adalimumab on First Line With Therapeutic Drug Concentration.

Recruiting·—·Phase 4·NCT06180382·220 enrolled

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease

Withdrawn· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT04655807

TDM Guided Early Optimization of ADAL in Crohn's Disease

Active, not recruiting·Wwaqqas.afif·N/A·NCT03261102·200 enrolled

Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon

Completed·AAbbott·Phase 3·NCT00348283·135 enrolled

Remission in Subjects With Crohn's Disease, Open Label Extension

Completed·AAbbott·Phase 3·NCT01070303·177 enrolled

Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial

Completed·SSchneider Children's Medical Center, Israel·Phase 4·NCT02256462·82 enrolled

Arthritis10 trials

Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis

Recruiting·TTom Appleton·Phase 2·NCT06037811·30 enrolled

Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA)

Completed· AbbVie logo

AbbVie·Phase 3·NCT01064856·165 enrolled

Study of Adalimumab in Patients With Axial Spondyloarthritis

Completed· AbbVie logo

AbbVie·Phase 3·NCT00939003·192 enrolled

Show 7 more trials

Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01808118·673 enrolled

Danish Multicenter Study of Adalimumab in Spondyloarthritis

Unknown status·GGlostrup University Hospital, Copenhagen·Phase 4·NCT00477893·52 enrolled

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)

Active, not recruiting·BBiocad·Phase 3·NCT06333210·421 enrolled

Efficacy of Humira in Behcet Patients With Arthritis

Completed·RRambam Health Care Campus·Phase 3·NCT01497717·9 enrolled

A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment

Terminated· AbbVie logo

AbbVie·Phase 4·NCT02897115·22 enrolled

A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis

Completed· AbbVie logo

AbbVie·Phase 3·NCT01166282·46 enrolled

Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis

Unknown status·UUniversity of Helsinki·Phase 4·NCT02634541·60 enrolled

Ulcerative Colitis9 trials

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors

Completed· Roche logo

Roche·Phase 3·NCT02171429·358 enrolled

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02632175·59 enrolled

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis

Completed·AAbbott·Phase 3·NCT00385736·576 enrolled

Show 6 more trials

Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02065557·101 enrolled

Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis

Unknown status·SShandong Qilu Stem Cells Engineering Co., Ltd.·N/A·NCT04882683·50 enrolled

Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)

Terminated·AAlimentiv Inc.·Phase 2·NCT01716039·22 enrolled

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

Completed·AAbbott·Phase 3·NCT00408629·518 enrolled

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT00853099·274 enrolled

Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

Completed· AbbVie logo

AbbVie·Phase 3·NCT02065622·952 enrolled

Inflammatory Bowel Disease4 trials

Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary (VALUE)

Completed· AbbVie logo

AbbVie··NCT02750800·427 enrolled

De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease

Enrolling by invitation·UUniversity Medical Center Groningen·Phase 4·NCT04646187·148 enrolled

Fluorescence Imaging of Adalimumab-680LT and Risankizumab-800CW in Inflammatory Bowel Disease

Not yet recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT07258641·30 enrolled

Show 1 more trial

Fluorescence Imaging of Adalimumab-680LT in Inflammatory Bowel Disease

Recruiting·UUniversity Medical Center Groningen·Phase 1/2·NCT06117423·21 enrolled

Efficacy and Safety4 trials

Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA

Completed·CCinnagen·Phase 3·NCT03172325·136 enrolled

Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate

Unknown status·KKeio University·Phase 4·NCT01270035·40 enrolled

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

Completed· Pfizer logo

Pfizer·Phase 4·NCT02187055·1,152 enrolled

Show 1 more trial

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

Approved for marketing·AAbbott··NCT00650390

Immunogenicity4 trials

Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male Subjects

Completed·SSamsung Bioepis Co., Ltd.·Phase 1·NCT04514796·188 enrolled

Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

Completed·TTurgut İlaçları A.Ş.·Phase 1·NCT04439929·168 enrolled

A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.

Completed· GSK logo

GSK·Phase 1·NCT01899755·45 enrolled

Show 1 more trial

Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®

Unknown status·MMabscale, LLC·Phase 3·NCT06005532·494 enrolled

Moderate to Severe Crohn's Disease3 trials

Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)

Completed·AAbbott·Phase 3·NCT00427921·304 enrolled

Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT02065570·514 enrolled

Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease

Completed· AbbVie logo

AbbVie·Phase 3·NCT01235689·252 enrolled

Tics3 trials

Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01505491·193 enrolled

Pharmacokinetics and Safety in Healthy Volunteers

Completed·SSinocelltech Ltd.·Phase 1·NCT03917628·146 enrolled

Pharmacokinetics and Safety in Healthy Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02045979·327 enrolled

Hidradenitis Suppurativa3 trials

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

Completed·AAbbott·Phase 2·NCT00918255·154 enrolled

To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa

Completed·FFlorida Academic Dermatology Centers·Phase 2·NCT00827996·10 enrolled

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

Completed· AbbVie logo

AbbVie·Phase 3·NCT01468233·326 enrolled

Crohn's Disease (CD)2 trials

Triple Combination Therapy in High Risk Crohn's Disease (CD)

Completed· Takeda logo

Takeda·Phase 4·NCT02764762·55 enrolled

Adalimumab for the Management of Post-operative Crohn's Disease (CD)

Unknown status·TTel-Aviv Sourasky Medical Center·Phase 3·NCT01629628·100 enrolled

Takayasu arteritis2 trials

A Pilot Study in Severe Patients With Takayasu Arteritis.

Recruiting·SShanghai Zhongshan Hospital·Phase 4·NCT04300686·40 enrolled

Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission

Recruiting·MMarmara University·N/A·NCT07491913·40 enrolled

Pyoderma Gangrenosum2 trials

A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan

Completed· AbbVie logo

AbbVie·Phase 3·NCT03311464·22 enrolled

Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum

Withdrawn·WWake Forest University Health Sciences·Phase 2·NCT00690846

Dupuytren's Disease1 trial

Repurposing Anti-TNF for Treating Dupuytren's Disease

Completed·UUniversity of Oxford·Phase 2·NCT03180957·140 enrolled

Tocilizumab1 trial

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Completed·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT02963402·35 enrolled

Phase II Clinical Trial1 trial

Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical Trial

Completed·NNYU Langone Health·Phase 2·NCT00814255·32 enrolled

Juvenile Idiopathic Arthritis1 trial

Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

Completed· AbbVie logo

AbbVie·Phase 3·NCT00775437·32 enrolled

Interstitial Cystitis1 trial

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

Completed·IICStudy, LLC·Phase 3·NCT01295814·43 enrolled

Spondylarthropathies1 trial

TNFalfa Blocking Treatment of Spondylarthropathies

Completed·HHvidovre University Hospital·Phase 4·NCT00133315·50 enrolled

Pouchitis1 trial

Adalimumab in the Treatment of Chronic Pouchitis

Completed·OOdense University Hospital·Phase 3·NCT01670240·13 enrolled

Methotrexate1 trial

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

Terminated· Sanofi logo

Sanofi·Phase 3·NCT01764997·776 enrolled

Age1 trial

Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects

Completed·—·Phase 1·NCT02252809·51 enrolled

Sarcoidosis1 trial

A Study of Adalimumab to Treat Sarcoidosis of the Skin

Completed·PPariser, Robert J., M.D.·Phase 2·NCT00274352·16 enrolled

Choroidal Neovascularization1 trial

Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study

Unknown status·RRafic Hariri University Hospital·Phase 1·NCT00855608·15 enrolled

Osteoarthritis1 trial

A Pilot Trial of Adalimumab for the Treatment of Osteoarthritis

Completed·SStanford University·Phase 2·NCT00185562·12 enrolled

MPA1 trial

Comparative Safety, Tolerability, Pharmacokinetic Study of AVT02 (100MG/ML) and Humira (100MG/ML) in Healthy Volunteers

Completed·AAlvotech Swiss AG·Phase 1·NCT03579823·24 enrolled

Fluorescence1 trial

Fluorescence Imaging of IBD and RA Using Adalimumab-800CW

Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT03938701·36 enrolled

Dendritic Cell1 trial

Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After TNF Alfa Inhibitors Therapy

Unknown status·UUniversity of Padova·Phase 4·NCT01237262·20 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Adalimumab in Patients Who Showed an Unsatisfactory Response to Etanercept

Completed·IInnovaderm Research Inc.·Phase 3·NCT00927069·85 enrolled

Adult Subject1 trial

Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects

Completed·SSynermore Biologics Co., Ltd.·Phase 1·NCT03254810·94 enrolled

Giant Cell Arteritis1 trial

HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00305539·69 enrolled

Atopic Dermatitis1 trial

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

Concentration1 trial

Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity

Completed·—·Phase 4·NCT04222920·78 enrolled

COVID-191 trial

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

Withdrawn·AAlachua Government Services, Inc.·Phase 3·NCT04705844

Systemic Therapy1 trial

Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy

Completed·AAbbott·Phase 3·NCT00566722·152 enrolled

Mucopolysaccharidosis1 trial

Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI

Completed·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 1/2·NCT02437253·2 enrolled

Bone Resorption1 trial

Bone Resorption, Osteoclastogenesis and Adalimumab

Unknown status·UUniversité de Sherbrooke·Phase 4·NCT02035800·120 enrolled

Joint Disease1 trial

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

Completed·JJonathan Graf·Phase 4·NCT01893996·63 enrolled

Obstructive Sleep Apnea1 trial

Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea

Completed·IInnovaderm Research Inc.·Phase 4·NCT01181570·20 enrolled

Generalized Pustular Psoriasis1 trial

Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

Completed· AbbVie logo

AbbVie·Phase 3·NCT02533375·10 enrolled

BPH1 trial

Effects of TNF Blockade on Human BPH/LUTS

Recruiting·EEndeavor Health·Phase 2·NCT06062875·70 enrolled

Unspecified2 trials

Long Term Open Label Continuation Study

Completed·AAbbott·Phase 3·NCT00195650·846 enrolled

Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease

Completed·HHospital Universitari Vall d'Hebron Research Institute·N/A·NCT02539849·38 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 31, 2002

Humira

BLA 125057

Dec 31, 2002

HUMIRA

BLA BLA125057

Oct 30, 2018

ADALIMUMAB

BLA BLA761071

Jul 23, 2019

HADLIMA

BLA BLA761059

May 23, 2023

ADALIMUMAB

BLA BLA761219

Sources

References

[1]
ClinicalTrials.gov — 413 trial records for Adalimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Humira drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Adalimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Adalimumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (BLA BLA761219). U.S. Food & Drug Administration.
[6]
PubMed — 10 publications indexed for Adalimumab. U.S. National Library of Medicine.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: TNF-Alpha Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Novartis

Key Publications[6]

Exploring emotional intelligence through emotional journaling: a qualitative study of young students.

Int J Qual Stud Health Well-beingDec 31, 2026DOI: 10.1080/17482631.2026.2688506

"It's taken away the most fundamental things about being human": the lived experience and impact of post-SSRI sexual dysfunction.

Int J Qual Stud Health Well-beingDec 31, 2026DOI: 10.1080/17482631.2026.2717470

Mott-Schottky Interface in Bi(2)Fe(4)O(9)/Ag Boosting Piezocarriers Separation for Hydroxychloroquine Degradation.

ChemSusChemAug 27, 2026DOI: 10.1002/cssc.70959

Liraglutide and Βeta-Cell Function in Young Adults With Long-Standing Type 1 Diabetes and Residual C-Peptide: A Blinded, Randomized Controlled Trial.

Diabetes Obes MetabAug 13, 2026DOI: 10.1111/dom.71204

Cervical pseudolymphoma following lamotrigine treatment: A clinical vignette.

Epileptic DisordAug 13, 2026DOI: 10.1002/epd2.70321

An Algorithm for the Diagnosis and Treatment of Allergic Contact Dermatitis (ACD).

AllergyAug 13, 2026DOI: 10.1111/all.70479

Exploration of Patient Adherence to Physician Recommendations in Laryngology Clinics.

LaryngoscopeAug 13, 2026DOI: 10.1002/lary.70740

Beyond current standards: combination therapy and emerging targets in diabetic kidney disease.

Kidney Res Clin PractAug 13, 2026DOI: 10.23876/j.krcp.26.234

Enzyme-driven antimicrobial resistance and advancements in sustainable anti-infective strategies.

Crit Rev BiotechnolAug 13, 2026DOI: 10.1080/07388551.2026.2693159

Current trends and advances of microbial biosurfactants in the biomedical and pharmaceutical applications.

Crit Rev BiotechnolAug 13, 2026DOI: 10.1080/07388551.2026.2711971

Humira

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Rheumatoid Arthritis41 trials

Psoriasis24 trials

Adalimumab18 trials

Uveitis11 trials

Ankylosing Spondylitis10 trials

Psoriatic Arthritis10 trials

Crohn's Disease10 trials

Arthritis10 trials

Ulcerative Colitis9 trials

Inflammatory Bowel Disease4 trials

Efficacy and Safety4 trials

Immunogenicity4 trials

Moderate to Severe Crohn's Disease3 trials

Tics3 trials

Hidradenitis Suppurativa3 trials

Crohn's Disease (CD)2 trials

Takayasu arteritis2 trials

Pyoderma Gangrenosum2 trials

Dupuytren's Disease1 trial

Tocilizumab1 trial

Phase II Clinical Trial1 trial

Juvenile Idiopathic Arthritis1 trial

Interstitial Cystitis1 trial

Spondylarthropathies1 trial

Pouchitis1 trial

Methotrexate1 trial

Age1 trial

Sarcoidosis1 trial

Choroidal Neovascularization1 trial

Osteoarthritis1 trial

MPA1 trial

Fluorescence1 trial

Dendritic Cell1 trial

Safety and Efficacy1 trial

Adult Subject1 trial

Giant Cell Arteritis1 trial

Atopic Dermatitis1 trial

Concentration1 trial

COVID-191 trial

Systemic Therapy1 trial

Mucopolysaccharidosis1 trial

Bone Resorption1 trial

Joint Disease1 trial

Obstructive Sleep Apnea1 trial

Generalized Pustular Psoriasis1 trial

BPH1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Key Publications[6]

Related News